A Cochrane Review of 9 trials confirmed HBOT relieves acute migraine pain, but the evidence for preventing future migraines is weak. In one randomized trial, 9 out of 10 patients experienced significant relief during HBOT sessions. The distinction matters: high-flow oxygen is well-established for cluster headaches, while HBOT’s role in migraine management is still preliminary. It is part of a broader group of pain conditions studied with HBOT that are being studied in hyperbaric research.
How HBOT May Help Migraines
Migraine pathophysiology is complex and not fully understood. Current models point to cortical spreading depolarization, neurogenic inflammation, and dysfunction in brainstem pain-modulating circuits. Several proposed mechanisms explain why pressurized oxygen could have an effect on these processes. This is something we explore further in our brain injury and concussion recovery.
In a randomized trial, 9 out of 10 migraine patients experienced significant relief with hyperbaric oxygen at 2 ATA, compared to just 1 out of 10 with normobaric oxygen.”
Myers & Myers, Headache, 1995
Reduced Cerebral Inflammation
Neurogenic inflammation plays a central role in migraine attacks. The release of calcitonin gene-related peptide (CGRP) and other neuropeptides triggers vasodilation and inflammation around meningeal blood vessels. HBOT has demonstrated anti-inflammatory effects in other contexts, including reduction of pro-inflammatory cytokines like TNF-alpha and IL-6. Researchers hypothesize that these same anti-inflammatory properties could dampen the neuroinflammatory cascade involved in migraines.
Improved Cerebral Blood Flow and Oxygen Delivery
Some migraine patients show evidence of cerebral hypoperfusion, particularly during the aura phase. By dramatically increasing the partial pressure of dissolved oxygen in the blood, HBOT can deliver oxygen to brain tissue even when normal hemoglobin-based transport is compromised. This hyperoxygenation may help normalize blood flow patterns and reduce the ischemic-like conditions that some researchers believe contribute to migraine attacks.
Nitric Oxide Pathway Modulation
Nitric oxide (NO) is a potent vasodilator implicated in migraine pathophysiology. Elevated NO levels can trigger migraine attacks in susceptible individuals, and many acute migraine medications work partly by counteracting NO-mediated vasodilation. HBOT influences NO metabolism through several pathways, including modulation of nitric oxide synthase (NOS) activity. This modulation may help regulate the vascular tone disruptions associated with migraines.
Neuroplasticity and Pain Sensitization
Chronic migraine involves central sensitization, where the brain’s pain-processing networks become increasingly reactive over time. Some HBOT research in traumatic brain injury and fibromyalgia suggests that repeated sessions may promote neuroplastic changes in pain-processing regions. Whether this translates to meaningful benefit for migraine patients remains an open question. For a deeper dive, check out our HBOT for fibromyalgia.
Research Evidence
The honest assessment: research on HBOT specifically for migraines is limited in both quantity and quality. A Cochrane systematic review examined normobaric and hyperbaric oxygen therapy for migraine and cluster headaches. The review found that while there was some evidence suggesting hyperbaric oxygen could reduce pain in acute migraine attacks, the included studies were small, methodologically varied, and insufficient to draw firm conclusions. The reviewers noted the need for larger, well-designed randomized controlled trials before any clinical recommendation could be made. For a detailed breakdown, read our systematic review on HBOT for migraines.
Several small studies have reported positive findings. One trial found that a course of HBOT sessions reduced migraine frequency and severity compared to a sham control. Another small study observed improvements in pain scores and a reduction in the number of monthly migraine days. However, these studies typically enrolled fewer than 50 participants, used varying protocols, and had short follow-up periods.
The placebo effect is a significant concern in migraine research generally, and HBOT studies face additional challenges. True sham-controlled HBOT trials are difficult to design because participants may detect pressure changes, potentially unblinding the study. This methodological limitation makes it harder to isolate the true therapeutic effect from expectation-driven improvement.
For a broader look at what hyperbaric oxygen research covers, see our HBOT research overview.
Oxygen Therapy for Cluster Headaches vs. Migraines
This distinction matters because these two conditions are often confused, and the evidence base for oxygen therapy differs dramatically between them.
Cluster Headaches: Strong Evidence for Oxygen
High-flow normobaric oxygen (delivered at 12 to 15 liters per minute via a non-rebreather mask for 15 to 20 minutes) is a first-line acute treatment for cluster headaches. It is backed by multiple randomized controlled trials and endorsed by major headache societies including the American Headache Society. Roughly 70% of cluster headache patients experience significant relief with high-flow oxygen. This is not HBOT. It is oxygen delivered at normal atmospheric pressure, and it works through different mechanisms than pressurized chamber therapy.
Migraines: Limited and Preliminary Evidence
HBOT for migraines lacks the same level of evidence. There are no major clinical guidelines recommending HBOT as a migraine treatment. The studies that do exist are promising enough to warrant further research but not strong enough to consider HBOT a validated migraine therapy. If someone tells you “oxygen therapy works for headaches,” they are likely referring to the cluster headache data, which does not directly apply to migraines. Want the details? Read our Mayo Clinic migraine overview.
Patients should be cautious about clinics that conflate the two conditions or cite cluster headache evidence when marketing HBOT for migraines.
Treatment Protocols
There is no standardized HBOT protocol for migraines. This is partly because there has not been enough research to determine optimal parameters. That said, most studies and clinics offering HBOT for migraines use protocols in the following range:
- Pressure: 1.5 to 2.4 ATA (atmospheres absolute), with most migraine-related studies using pressures between 1.5 and 2.0 ATA
- Session duration: 60 to 90 minutes per session
- Number of sessions: Typically 10 to 20 sessions over a period of 2 to 6 weeks
- Frequency: Usually 5 sessions per week (weekdays)
Some clinics offer maintenance sessions after the initial course, though the evidence for ongoing treatment is even more limited than for the initial protocol. The lack of standardization means your experience may vary considerably depending on the provider. For more on what a typical course looks like, see our guide to HBOT sessions.
What Does the HBOT Protocol Look Like?
If you decide to try HBOT for migraines, here is a general overview of the process:
Before treatment: You will typically have a consultation to review your medical history and migraine patterns. The provider should discuss the limited evidence base honestly and set realistic expectations. You may be asked about contraindications including untreated pneumothorax, certain ear conditions, and claustrophobia during HBOT.
During treatment: You will enter a pressurized chamber (either a monoplace chamber for one person or a multiplace chamber shared with others). As the chamber pressurizes, you will feel pressure in your ears similar to descending in an airplane. You can equalize by swallowing, yawning, or using the Valsalva maneuver. Once at target pressure, you breathe normally or through a mask for the prescribed duration. Most people read, watch a screen, or rest during the session.
After treatment: Sessions are generally well-tolerated. Some people feel temporarily lightheaded or fatigued afterward. Ear discomfort is the most common side effect. Serious complications are rare but worth understanding before you begin. Read more about potential HBOT side effects.
Cost considerations: HBOT for migraines is unlikely to be covered by insurance, as it is not an FDA-approved indication. Sessions typically cost HBOT session costs to $400 each, which means a full 20-session course could run $3,000 to $8,000 out of pocket. For details on coverage, see our HBOT insurance guide.
A Cochrane Review of 9 trials confirmed HBOT effectively relieved acute migraine pain, though it did not demonstrate a preventive effect on future episodes.”
Bennett et al., Cochrane Database, 2008
Frequently Asked Questions
Can HBOT cure migraines?
There is no evidence that HBOT cures migraines. Some small studies suggest it may reduce the frequency or intensity of attacks in certain patients, but it has not been shown to eliminate migraines entirely. Migraines are a complex neurological condition with multiple contributing factors, and no single treatment works as a cure for most people. HBOT should be viewed as a potential complementary approach, not a replacement for established migraine management strategies.
Is HBOT safe for people who get migraines with aura?
HBOT is generally considered safe for migraine patients, including those who experience aura. However, there is very little research examining HBOT specifically in the migraine-with-aura subgroup. Because aura involves transient cortical changes and some degree of cerebral blood flow alteration, it is reasonable to discuss this with both your neurologist and the HBOT provider before starting treatment. The standard contraindications for HBOT apply regardless of migraine subtype.
How many HBOT sessions are needed to see results for migraines?
Most studies used protocols ranging from 10 to 20 sessions, with some patients reporting improvement after the first 5 to 10 sessions. However, individual responses vary widely, and some patients may complete a full course without noticeable benefit. Given the cost per session and the limited evidence, it is worth setting a clear evaluation point with your provider. If you do not notice any change after 10 sessions, continuing may not be worthwhile.
References
- Myers D, Myers RA.. “A Preliminary Report on Hyperbaric Oxygen in the Relief of Migraine Headache.” Headache, 1995. DOI: 10.1111/j.1526-4610.1995.hed3504197.x
- Wilson JR, et al.. “Hyperbaric Oxygen in the Treatment of Migraine With Aura.” Headache, 1998. DOI: 10.1046/j.1526-4610.1998.3802112.x
- Bennett MH, et al.. “Normobaric and hyperbaric oxygen therapy for migraine and cluster headache.” Cochrane Database of Systematic Reviews, 2008. DOI: Cochrane Review
- Eftedal O, et al.. “Randomized double-blind study of prophylactic hyperbaric oxygen therapy for migraine.” Cephalalgia, 2004. DOI: 10.1111/j.1468-2982.2004.00724.x
- Shafee R, et al.. “Case report: chronic migraine treated with HBOT.” EMJ Neurology, 2021. DOI: 10.33590/emjneurol/20-00262
- Undersea and Hyperbaric Medical Society. “HBO Therapy Indications.” UHMS, 2024. DOI: uhms.org
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
